Similar to the results of patients with intermediate and adverse-cytogenetic risk, IPM-HR, older age, TP53 mutation, FLT3-ITD, and DNMT3A mutation were all independent adverse prognostic factors for OS in non-M3 AML patients (Table 1). This evidence concerns the gene TP53 and acute myeloid leukemia.